Parkinsons Disease Biomarkers Market Size, Share and Trends 2026 to 2035

What is the Parkinson's Disease Biomarkers Market Size in 2026?

The global parkinsons disease biomarkers market size accounted for USD 1.35 billion in 2025 and is predicted to increase from USD 1.54 billion in 2026 to approximately USD 4.88 billion by 2035, expanding at a CAGR of 13.80% from 2026 to 2035. The market is driven by the rising demand for early diagnosis and disease-modifying therapies.

Key Takeaways

• North America dominated the global market with a share of 43% in 2025.
• Asia-Pacific is expected to grow at the fastest CAGR of 17.2% during the forecast period.
• By biomarker type, the molecular biomarkers segment contributed 38% revenue share in 2025.
• By biomarker type, the genetic biomarkers held 18% of the Parkinson's disease biomarkers market share in 2025 and is expected to grow at the fastest CAGR of 15% in the coming years.
• By technology, the immunoassays segment accounted for a revenue share of 28% in the market in 2025.
• By technology, the AI-based biomarker analysis segment held 5% share and is expected to grow at the highest CAGR 22% between 2026 and 2035.
• By application, the early diagnosis segment led the global market with a share of 36% in 2025 and is expected to grow at the fastest CAGR of 16.5% between 2026 and 2035.
• By end-use, the hospitals segment accounted for a revenue share of 38% in the market in 2025.
• By end-use, the diagnostic laboratories segment held a market share of 26% in 2025 and is expected to grow at the fastest CAGR of 15.5% between 2026 and 2035.

Market Overview

Biomarkers in Parkinson's disease (PD) are substances in the body that provide researchers and doctors with information about a person's health. PD biomarkers are measurable biological indicators such as misfolded alpha-synuclein in spinal fluid or skin biopsies, widely used for early diagnosis, tracking disease progression, improving clinical trials, and evaluating treatment efficacy. Standard PD diagnosis relies on neurological exams, symptom history, and response to dopamine therapies.

How are AI-driven Innovations Impacting the Growth of the Parkinson's Disease Biomarkers Market?

In the rapidly evolving technological landscape, the integration of artificial intelligence (AI) emerges as a changer and is driving the growth of the market by allowing early detection, enabling more sophisticated data analysis, and enhancing diagnostic accuracy. AI algorithms can process data from smartphones and wearable sensors to track tremors, gait, and voice in real-time. Machine learning (ML) is significantly enhancing the accuracy of early detection by analyzing voice patterns, video-based movement analyses, and breathing patterns during sleep. AI is broadly utilized to identify subtle motor and non-motor patterns that appear years before formal diagnosis. AI-driven innovations allow for earlier detection, continuous monitoring, and the discovery of new molecular signatures, accelerating the market expansion.

What are the Emerging Trends in the Market?

• The increasing investments in neurological research is expected to accelerate the growth of the market. Several pharmaceutical companies and research institutions are increasingly allocating resources to advance the understanding and development of neurological biomarkers.
• The rising shift towards minimally invasive techniques, particularly blood-based markers, is anticipated to promote the market's growth during the forecast period.
• The growing prevalence of PD biomarkers globally has created an increasing need for more accurate and efficient diagnostic tools, boosting the adoption of biomarker-based diagnostics.
• The rising introduction of novel blood-based biomarkers has revolutionized the diagnostic landscape, contributing to the overall growth of the market. Blood-based biomarkers offer a minimally invasive solution to detect and monitor PD, paving the way for improved patient outcomes and accelerated drug development.
• The rising critical role of biomarkers in accelerating clinical trials for disease-modifying therapies is expected to fuel the growth of the market during the forecast period. The PD clinical trials require reliable, objective biomarkers for patient stratification, measuring target engagement, and demonstrating efficacy.

Market Scope

Market Dynamics

Drivers

Rising Need for Early Diagnosis

The growing need for early diagnosis is expected to boost the growth in the market. Biomarkers can detect PD in its prodromal (pre-symptomatic) stage. Early diagnosis is crucial for testing and adopting advanced therapies that aim to stop or slow progression rather than just treating symptoms. Several researchers believe biomarkers hold the possibility to diagnose PD earlier and with greater precision. Biomarkers assist in tracking disease progression and whether someone is responding to treatment.

Restraint

High Costs Associated with Biomarker Development

The rising cost of development of biomarkers is anticipated to hamper the growth of the market. The development of specialized biomarker assays is expensive, which limits their adoption. In addition, the stringent regulatory approvals may hinder the growth of the global parkinson's disease biomarkers market during the forecast period.

Opportunity

Increasing Demand for Personalized Treatment

The increasing demand for personalized treatment is anticipated to present a lucrative growth opportunity for the market. Personalized medicine uses genetic and biochemical biomarkers to tailor treatments to individual profiles. Biomarkers enable personalized treatment strategies by distinguishing subtypes of Parkinson's disease, which assist in selecting the most effective disease-modifying therapies, thereby increasing the significant demand for diagnostic, prognostic, and therapeutic response markers.

Segment Insights

Biomarker Type Insights

Parkinson's Disease Biomarkers Market Share, By Biomarker Type, 2025-2035 (%)

The Molecular Biomarkers Segment Held a 38% Market Share in 2025

The molecular biomarkers segment dominated the Parkinson's disease biomarkers market with a 38% share in 2025, due to the increasing adoption of non-invasive and blood-based testing. The discovery and application of phosphorylated alpha-synuclein in Seed Amplification Assays (SAAs) and blood-based assays have strengthened the position of molecular assays as the critical tool for identifying and validating PD patients. Molecular biomarkers enable the monitoring of disease progression and the evaluation of therapeutic responses in clinical trials, particularly for the development of disease-modifying therapies.

The imaging biomarkers segment held the second-largest market share of 30% in 2025, owing to its high diagnostic accuracy in detecting neurodegeneration, particularly through advancements in SPECT, MRI, and PET scans that visualize structural and functional brain changes. Imaging techniques are highly effective at evaluating the dopamine system, which is crucial for identifying Parkinson's disease and distinguishing it from other disorders. Hospitals and clinics are increasingly relying on these imaging modalities for immediate patient assessment.

The genetic biomarkers segment held 18% of the market share in 2025 and is expected to grow at the highest CAGR of 15% during the forecast period, owing to its critical role in enabling early diagnosis, guiding personalized therapeutic development, and the discovery of significant gene mutations. The rising shift toward personalized treatment plans requires genetic screening to identify specific mutations, which allows for tailoring therapies based on a patient's genetic profile. Genetic biomarkers assist in identifying at-risk individuals, even before motor symptoms appear, which is critical for potential disease-modifying treatments.

Technology Insights

Parkinson's Disease Biomarkers Market Share, By Technology, 2025-2035 (%)

Why Did the Immunoassays Segment Led the Market in 2025?

The immunoassays segment held a dominant position in the Parkinson's disease biomarkers market with a market share of 28% in 2025, driven by the increasing availability, cost-effectiveness, scalability, and critical performance in detecting key protein biomarkers such as α-synuclein, DJ-1, and NfL. They are considered primary technology for measuring pathological alpha-synuclein, which is crucial for differentiating Parkinson's disease from other neurodegenerative diseases. Immunoassays allow for rapid testing of many samples, essential in both research and clinical diagnostics.

The AI-based biomarker analysis segment held a 5% share of the market in 2025 and is expected to grow at the fastest CAGR of 22% during the forecast period, driven by its ability to process complex and large-scale data for early and accurate diagnosis. AI can effectively detect subtle and hidden patterns in multimodal data, including genetic markers, neuroimaging, and digital signatures from voice or wearable movement trackers, which are often overlooked by human clinicians. AI algorithms significantly improve diagnostic accuracy by differentiating PD from other related conditions.

The molecular diagnostics segment held 24% of the market share in 2025, driven by the increasing need for early diagnosis that traditional clinical evaluations are unable to provide. Moreover, the rising development of highly accurate seeding assays that detect pathological misfolded proteins, along with the rapid advancements in blood-based testing, is bolstering the segment's growth during the forecast period.

Application Insights

The Early Diagnosis Segment Held a 36% Share of the Market in 2025

The early diagnosis segment held a dominant position in the Parkinson's disease biomarkers market with a share of 36% in 2025 and is expected to grow at the fastest CAGR 16.5% during the projection period. The growth of the segment is attributed to the increasing need for identifying the disease in its pre-symptomatic stages, which plays a crucial role in maximizing the effectiveness of potential disease-modifying therapies. Early diagnosis assists in initiating therapies that can slow down or stop the progression of Parkinson's disease, as traditional treatment usually starts only after certain neuronal damage has occurred.

Parkinson's Disease Biomarkers Market Share, By Application, 2025-2035 (%)

The disease progression monitoring segment is the second-largest shareholder with a share of 28% in 2025. This is mainly due to the rising need for objective tools to track the slow, chronic, and degenerative nature of the disease. Moreover, the rising shift toward disease-modifying therapies rather than mere symptomatic relief is anticipated to bolster the segment's expansion.

The drug discovery and development segment held a 18% market share in 2025 and is expected to grow at a CAGR of 13% in the upcoming period, driven by their intense research into disease-modifying therapies and a surge in clinical trials requiring patient stratification. The growing need to bring new drugs to the market has encouraged the pharmaceutical companies to heavily invest in biomarker adoption. Biomarkers play an indispensable role in identifying patients at early stages of PD, a requirement for trials targeting disease modification.

End-Use Insights

What Made Hospitals the Dominant Segment in the Parkinson's Disease Biomarkers Market?

The hospitals segment dominated the global market with the largest share of 38% in 2025. Hospitals are the leading adopters of advanced and high-sensitivity diagnostic technologies such as the Syn-one skin biopsy. The rising complex interpretation of biomarker data requires skilled neurologists, who are generally concentrated within hospital settings. As the population of PD patients grows, there is a greater emphasis on utilizing biomarkers such as cerebrospinal fluid analysis, imaging, and skin biopsies for the early and prodromal detection and monitoring of disease progression, which requires professional clinical care environments in hospital settings.

Parkinson's Disease Biomarkers Market Share, By End-Use, 2025-2035 (%)

The diagnostic laboratories segment held a 26% share of the market in 2025 and is expected to grow at the fastest CAGR of 15.5% during the projection period. This is mainly due to the growing need for early and accurate disease detection, the increasing burden of PD, rapid advancements in enzyme-linked immunosorbent assays (ELISA), and rising adoption of blood-based biomarker testing like NfL and alpha-synuclein.

The academic and research institutes segment held a 18% market share in 2025 and is expected to grow at a notable CAGR of 12.5% during the projection period, owing to their role in discovery research, extensive longitudinal studies, and rising reliance on advanced molecular diagnostics. These institutes lead in exploring advanced biomarkers, such as α-synuclein, and establishing the validation needed for clinical application. Before biomarkers are utilized in clinical diagnostics, they must undergo rigorous testing in research laboratories. The development of Seed Amplification Assays (SAAs) to detect misfolded alpha-synuclein in fluid samples was mainly driven by academic research.

Regional Insights

North America Parkinson's Disease Biomarkers Market Size and Growth 2026 to 2035

The North America Parkinsons disease biomarkers market size was exhibited at USD 580 million in 2025 and is projected to be worth around USD 1,970 million by 2035, growing at a CAGR of 13.00% from 2026 to 2035.

Which Factors Drive the Parkinson's Disease Biomarkers Market in North America?

North America led the market by holding a major share of 43% in 2025 due to the advanced healthcare infrastructure, rising burden of Parkinson's disease, increasing need for early diagnosis, surging demand for blood-based biomarkers, supportive government policies, and rapid advancements in enzyme linked immunosorbent assays (ELISA). Additionally, the rising investments in identifying disease-modifying therapies are driving the increasing use of biomarkers to measure treatment efficacy, accelerating the market's growth in the region.

U.S. Parkinson's Disease Biomarkers Market Size and Growth 2026 to 2035

The U.S. Parkinsons disease biomarkers market size was evaluated at USD 440.00 million in 2025 and is projected to reach around USD 1,520.00 million by 2035, growing at a CAGR of 13.09% from 2026 to 2035.

U.S. Market Trends

The U.S. is a major contributor to the North American market. The country is home to the leading market players such as F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Thermo Fisher Scientific, Abbott Laboratories, and others. The country leads in developing novel biomarkers, such as the alpha-synuclein seeding amplification assay. The field of neurological biomarkers is experiencing significant growth in research funding and investment, particularly from both public and private sectors in the country. Additionally, the rising support from government agencies and funding for research enables the rapid adoption of new and advanced diagnostics.

According to the Parkinson's Foundation, an estimated 1.1 million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Men are 1.5 times more likely to have Parkinson's disease than women.

How is Asia-Pacific Growing in the Parkinson's Disease Biomarkers Market?

Asia Pacific held 18% of the market share in 2025 and is expected to grow at the fastest CAGR of 17.2% during the projection period. The region has a developing healthcare infrastructure, which provides a robust environment for testing and validating new biomarkers. The rising aging population in countries like China, India, and Japan has increased the prevalence of PD, boosting the demand for early diagnosis and monitoring. Moreover, the rising adoption of advanced diagnostic technologies and increasing funding for research from both government and private sectors for blood-based and neuroimaging biomarkers. The region is also witnessing higher demand for non-invasive, accurate, and affordable diagnostic tools to support early intervention for Parkinson's disease, which is further accelerating the market's growth in the coming years.

China Market Trends

The Chinese market is driven by the growing burden of PD, significant investments in diagnostic infrastructure, the rise of precision medicine, a surge in the aging population, a rising focus on early detection, an increasing number of clinical trials, and rapid technological innovation. The rising integration of AI is being widely utilized in the country to analyze complex imaging and biochemical data to enhance diagnostic accuracy and identify drug targets. Additionally, the rising government initiatives and increasing investment in research support the development of novel biomarkers.

Parkinson's Disease Biomarkers Market Companies

• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories
• Thermo Fisher Scientific
• Abbott Laboratories
• Quanterix
• Siemens Healthineers
• GE HealthCare
• PerkinElmer
• Sysmex Corporation
• Biogen Inc.
• Pfizer Inc.
• Novartis AG
• Quest Diagnostics
• Labcorp
• Proteome Sciences

Recent Developments

• In April 2026, Biognosys Group and The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced a collaboration to develop sensitive and quantitative biomarker assays for Parkinson's disease. The partnership supports MJFF's LRRK2 Investigative Therapeutics Exchange (LITE), a global initiative designed to accelerate the development of therapies and biomarkers targeting leucine-rich repeat kinase 2 (LRRK2). (Source: https://clpmag.com)
• In November 2025, CND Life Sciences, Inc. (CND) announced that its Syn-One Biomarker Services had been used to measure and quantify a reduction in the deposition of abnormal alpha-synuclein in a Phase 2 clinical trial sponsored by ABLi Therapeutics for its lead investigational Parkinson's disease (PD) treatment, risvodetinib.(Source: https://www.prnewswire.com)

Segments Covered in the Report

By Biomarker Type

• Molecular Biomarkers
  
  • Alpha-synuclein
  • DJ-1 Protein
  • Tau Protein
  • Neurofilament Light Chain (NfL)
• Imaging Biomarkers
  
  • PET Imaging
  • MRI Biomarkers
  • SPECT Imaging
• Genetic Biomarkers
  
  • LRRK2 Mutation
  • GBA Mutation
  • SNCA Gene
• Biochemical Biomarkers
  
  • Cerebrospinal Fluid (CSF) Biomarkers
  • Blood-based Biomarkers
  • Salivary Biomarkers

By Technology

• Immunoassays
• Molecular Diagnostics
• Proteomics
• Genomics
• Neuroimaging Technologies
• AI-based Biomarker Analysis

By Application

• Early Diagnosis
• Disease Progression Monitoring
• Drug Discovery & Development
• Personalized Medicine
• Clinical Research

By End-use

• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes
• Specialty Neurology Clinics
• Pharmaceutical & Biotechnology Companies

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa